Pulmonx saw no growth in patent filings in May and highest growth of 0.99% in grants in June in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and grants by 0.49%. GlobalData’s DataBook provides a comprehensive analysis of Pulmonx’s patent filings and grants. Buy the databook here.
Pulmonx has been focused on protecting inventions in United States(US) with two publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 50% grants. The United States(US), Australia(AU), and European Patent Office(EPO) patent Office are among the top ten patent offices where Pulmonx is filings its patents. Among the top granted patent authorities, Pulmonx has 50% of its grants in United States(US) and 50% in Australia(AU).
Olympus could be the strongest competitor for Pulmonx
Pulmonx stands in second position with respect to its patent publications among its competitors.
Patents related to healthtech and machine learning lead Pulmonx's portfolio
Pulmonx has the highest number of patents in healthtech followed by, machine learning. For healthtech no patents were filed and 50% of patents were granted in Q2 2024.
Anesthesia and respiratory devices related patents lead Pulmonx portfolio followed by diagnostic imaging, and client computing & peripherals
Pulmonx has highest number of patents in anesthesia and respiratory devices followed by diagnostic imaging, client computing & peripherals, image management.
For comprehensive analysis of Pulmonx's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.